Scopolamine Market, By Dosage Form (Tablet, Syrup, Injection, Patch, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI1965

Pages :151

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

In January 2024, the U.S. FDA issued a complete response letter to Defender Pharmaceuticals, a pharmaceutical company, for its New Drug Application (NDA) of intranasal scopolamine gel (DPI-386) aimed at preventing motion-induced nausea and vomiting in adults. Clinical trials, including a phase 3 study, showed that intranasal scopolamine was more effective than placebo in reducing vomiting and rescue medication use.
In June 2023, Defender Pharmaceuticals, a pharmaceutical company, announced positive results from a pivotal Phase III clinical trial assessing the effectiveness of intranasal scopolamine in preventing nausea and vomiting induced by motion
In March 2022, Athira Pharma, Inc., a clinical-stage biopharmaceutical company, explored the use of scopolamine, an innovative small molecule being investigated for conditions such as Parkinson’s disease dementia, Alzheimer’s disease, and dementia with Lewy bodies. It also focused on ATH-1020; an oral brain-penetrating small molecule candidate aimed at treating neuropsychiatric disorders.
In July 2022, Bayer HealthCare Pharmaceuticals Inc. introduced its product Transderm-Scop, a skin patch, into both retail and online markets. This updated formulation, with a dosage of 1 mg per 72 hours, received approval from the U.S. Food and Drug Administration.